NIH VideoCast - Global Health Inequities and the Critical Role of Public/Private Partnerships

Skip Navigation

Global Health Inequities and the Critical Role of Public/Private Partnerships

Loading... Loading video...

Air date:	Thursday, June 12, 2003, 3:00:00 PM Time displayed is Eastern Time, Washington DC Local
Views:	Total views: 87 * This only includes stats from October 2011 and forward.
Category:	Special
Runtime:	01:09:40
Closed captioning:	Check box to display CC outside of the video Note: You can drag the captioning window around and resize it
Description:	Challenges and Opportunities in the Next Decade Fifth Fogarty International Center 35th Anniversary Global Health Lecture Gail Cassell, Ph.D. Vice President for Scientific Affairs Distinguished Lilly Research Scholar for Infectious Diseases Eli Lilly and Company

NLM Title:	Global health inequities and the critical role of public/private partnerships / Gail Cassell.
Author:	Cassell, Gail H. National Institutes of Health (U.S.)
Publisher:
Abstract:	In this lecture, Gail Cassell of the Eli Lilly Company discusses the implications of a rising global population, particularly in disease-prone regions. She notes that population is rapidly growing in eight countries in particular, seven of which are developing nations also afflicted with high rates of tuberculosis (TB). For example, India's population increases more in one week than does the European Union's in a year. Crowded conditions and lack of treatment result in rising numbers of TB infections and death. Cassell reports that in 1997, she received a call about Paul Farmer and Jim Kim's Partners in Health initiative, and its acute need for tuberculosis drugs known to be effective against multi-drug- resistant TB. Eli Lilly contributed these drugs for Partners in Health's work in Peru, and after four months, the initiative reported an 83.3 percent cure rate for those treated for multi-drug resistant TB. Eli Lilly also helped to train community workers, many of whom had little previous schooling, and took steps to bring the drugs and treatment method to other countries.
Subjects:	Delivery of Health Care Developing Countries Directly Observed Therapy Private Sector Tuberculosis, Multidrug-Resistant--economics Tuberculosis, Multidrug-Resistant--epidemiology Tuberculosis, Multidrug-Resistant--therapy
Publication Types:	Lecture Webcast
Rights:	This is a work of the United States Government. No copyright exists on this material. It may be disseminated freely.
NLM Classification:	WF 200
NLM ID:	101267571
CIT Live ID:	2429
Permanent link:	https://videocast.nih.gov/watch=2429

Related Videos...